Showing 16,261 - 16,280 results of 103,558 for search '(( 2 step decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.91s Refine Results
  1. 16261
  2. 16262
  3. 16263
  4. 16264

    Impact on Patients’ Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial by Anete Trajman (359740)

    Published 2015
    “…However, the overall TB-attributed death rate was lower in the intervention arm (2.3% vs. 3.8%). Adjusted for HIV status, age group and city, the intervention resulted in a 35% decrease in TB-attributed deaths (OR=0.65, 95%CI=0.44-0.97).…”
  5. 16265
  6. 16266
  7. 16267

    HE images of the adherent cells in the 2D and 3D scaffold systems. by Lucrezia Ferretti (18806152)

    Published 2024
    “…Instead, in SHR1 (5x magnification), SHR2 and SHR3 (10x magnification) the cells barely reached 50% confluence at 72h, then the cellularity decreased between 72h and 7 days (j-o). 2D culture (5x magnification) show a higher cellularity in each time point compared to scaffolds (a-c). …”
  8. 16268

    Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists by Dilip K. Tosh (1668115)

    Published 2018
    “…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
  9. 16269

    Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists by Dilip K. Tosh (1668115)

    Published 2018
    “…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
  10. 16270

    Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists by Dilip K. Tosh (1668115)

    Published 2018
    “…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
  11. 16271

    Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists by Dilip K. Tosh (1668115)

    Published 2018
    “…While screening off-target effects of rigid (<i>N</i>)-methanocarba-adenosine 5′-methylamides as A<sub>3</sub> adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). …”
  12. 16272
  13. 16273
  14. 16274

    Bald thigh syndrome in sighthounds—Revisiting the cause of a well-known disease by Magdalena A. T. Brunner (4532341)

    Published 2019
    “…Further research is required to clarify whether the <i>IGFBP5</i> variant represents a predisposing genetic risk factor. …”
  15. 16275
  16. 16276

    Stress-sensitive antidepressant-like effects of ketamine in the mouse forced swim test by Paul J. Fitzgerald (3239337)

    Published 2019
    “…This combination of fast action and a therapeutic effect that lasts far beyond the drug’s half-life points to a unique mechanism of action. …”
  17. 16277

    Synthesis, Crystal Structure, and Spectroscopic Characterization of a Series of Cubane-like Mo−Sb Clusters Containing a [Mo<sub>3</sub>SbOS<sub>3</sub>]<sup>7+</sup> Core by Shao-Fang Lu (2974926)

    Published 1999
    “…Crystal data:  <b>1</b>, triclinic, <i>P</i>-1, <i>a</i> = 11.746(4) Å, <i>b</i> = 12.462(3) Å, <i>c</i> = 17.851(6) Å, α = 73.54(2)°, β = 75.06(3)°, γ = 88.11(3)°, <i>V</i> = 2419(3) Å<sup>3</sup>, <i>Z</i> = 2, 4253 reflections, <i>R</i> = 0.055; <b>2</b>, triclinic, <i>P</i>-1, <i>a</i> = 12.76(1) Å, <i>b</i> = 17.86(1) Å, <i>c</i> = 11.882(4) Å, α = 75.05(4)°, β = 88.15(7)°, γ = 73.24(4)°, <i>V</i> = 2502(6) Å<sup>3</sup>, <i>Z</i> = 2, 1849 reflections, <i>R</i> = 0.086; <b>3</b>, triclinic, <i>P</i>-1, <i>a</i> = 11.727(4) Å, <i>b</i> = 12.951(3) Å, <i>c</i> = 17.957(4) Å, α = 73.52(3)°, β = 76.22(3)°, γ = 89.00(2)°, <i>V</i> = 2536(3) Å<sup>3</sup>, <i>Z</i> = 2, 6306 reflections, <i>R</i> = 0.053; <b>5</b>, triclinic, <i>P</i>-1, <i>a</i> = 13.261(4) Å, <i>b</i> = 13.529(4) Å, <i>c</i> = 12.535(8) Å, α = 101.54(3)°, β = 105.13(4)°, γ = 93.20(2)°, <i>V</i> = 2113(2) Å<sup>3</sup>, <i>Z</i> = 2, 4104 reflections, <i>R</i> = 0.060.…”
  18. 16278
  19. 16279
  20. 16280

    NaSal failed to increase excitability of 5-HTergic neurons in the absence of the GABAergic inhibition in the DRN of the ChR2 transgenic mouse. by Yan Jin (143500)

    Published 2015
    “…(B) Sample recordings from a 5-HTergic neuron showing that NaSal decreased voltage responses to a series of hyperpolarizing currents (-10 to -60 pA, -10 pA/step, duration: 500 ms). …”